Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 7:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 26 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: TR-701 Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Thorough QT Study of TR-701free Acid (FA) in Healthy Subjects

NCT01461460
View directory record Official record
Conditions
Healthy Volunteer
Interventions
TR-701 FA 1200 mg, Moxifloxacin 400 mg, TR-701 FA 200 mg plus Placebo, Placebo
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Sep 3, 2026, 7:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single and Multiple Ascending Dose Pharmacokinetic Study of TR701 in Healthy Adults

NCT00671814
View directory record Official record
Conditions
Healthy Subjects
Interventions
TR-701, linezolid, placebo
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 50 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Sep 3, 2026, 7:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A PK and Safety Study in Subjects With Hepatic Impairment

NCT01431833
View directory record Official record
Conditions
Hepatic Impairment
Interventions
TR-701 FA
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Orlando, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 19, 2016 · Synced Sep 3, 2026, 7:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Tedizolid Tissue Penetration in Diabetic Patients With Wound Infections and Healthy Volunteers Via In Vivo Microdialysis

NCT02620787
View directory record Official record
Conditions
Diabetes, Wound Infection, Healthy Volunteers
Interventions
Tedizolid, Microdialysis Catheter Insertion
Drug · Procedure
Lead sponsor
Hartford Hospital
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 14, 2019 · Synced Sep 3, 2026, 7:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Effects of Single Oral Dose of 600mg TR-701

NCT00671359
View directory record Official record
Conditions
Healthy
Interventions
TR-701 600mg
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Sep 3, 2026, 7:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Microdialysis and Pharmacokinetic Study of TR-701

NCT00666601
View directory record Official record
Conditions
Healthy
Interventions
TR-700 (active moiety), TR-701 (pro-drug)
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Sep 3, 2026, 7:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Oral Formulations of Tedizolid Phosphate in Healthy Participants (MK-1986-043)

NCT06733688
View directory record Official record
Conditions
Healthy
Interventions
Tedizolid Phosphate Oral Formulation 1 (Reference), Tedizolid Phosphate Oral Formulation 2 (Test)
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
19 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Sep 3, 2026, 7:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects

NCT01442831
View directory record Official record
Conditions
Healthy
Interventions
Human ADME
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Sep 3, 2026, 7:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 TR-701 FA Study of Blood Pressure Response Post Tyramine Challenge

NCT01539473
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TR-701 FA with Tyramine, Placebo-controlled withTyramine
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated May 2, 2016 · Synced Sep 3, 2026, 7:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Exploratory Pharmacokinetic and Bioavailability Study of 2 Capsule Formulations of Torezolid Phosphate

NCT00876655
View directory record Official record
Conditions
Healthy
Interventions
TR-701 di-sodium phosphate salt, TR-701 free acid phosphate
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 2, 2016 · Synced Sep 3, 2026, 7:27 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

NCT02066402
View directory record Official record
Conditions
Bacterial Infections
Interventions
Tedizolid (BAY119-2631), Placebo Tedizolid (BAY119-2631), Linezolid, Placebo Linezolid
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
598 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
5
States / cities
Chula Vista, California • La Mesa, California • Oceanside, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2017 · Synced Sep 3, 2026, 7:27 AM EDT
Completed Phase 2 Interventional Results available

Tolerability, Safety, and Efficacy of Tedizolid as Oral Treatment for Bone and Joint Infections (OTTER)

NCT03009045
View directory record Official record
Conditions
Bone and Joint Infection
Interventions
Tedizolid
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Sep 3, 2026, 7:27 AM EDT
Completed Phase 3 Interventional Results available

A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018)

NCT03176134
View directory record Official record
Conditions
Acute Bacterial Skin and Skin Structure Infections
Interventions
Tedizolid phosphate, Comparator
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
1 Day to 11 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
8
States / cities
San Diego, California • Chicago, Illinois • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Sep 3, 2026, 7:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pulmonary Disposition of TR-700 Following Once-Daily Oral 200 mg

NCT01271998
View directory record Official record
Conditions
Bacterial Infection
Interventions
TR-701 FA
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Sep 3, 2026, 7:27 AM EDT
Completed Phase 4 Interventional Results available

Pharmacokinetics of Tedizolid Phosphate in Cystic Fibrosis

NCT02444234
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Tedizolid PO, Tedizolid IV
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 1, 2020 · Synced Sep 3, 2026, 7:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Ascending Dose Pharmacokinetic (PK) and Absolute Bioavailability (BA)

NCT00983255
View directory record Official record
Conditions
Bacterial Infections
Interventions
TR-701 FA for injection, 200 mg/vial, TR-701 FA tablets
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 50 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Sep 3, 2026, 7:27 AM EDT
Completed Phase 1 Interventional Results available

A Pharmacokinetic Study of Tedizolid Phosphate in Pediatric Participants With Gram-Positive Infections (MK-1986-014)

NCT03217565
View directory record Official record
Conditions
Gram-Positive Infections
Interventions
IV Tedizolid Phosphate, Oral Suspension Tedizolid Phosphate
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
1 Day to 24 Months
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
7
States / cities
Little Rock, Arkansas • Orange, California • San Diego, California + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Sep 3, 2026, 7:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Crossover Study of Blood Pressure and Heart Rate Response

NCT01577459
View directory record Official record
Conditions
Healthy Subjects
Interventions
TR-701 FA with PSE, TR-701 FA Placebo with PSE
Drug · Other
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Sep 3, 2026, 7:27 AM EDT
Completed Phase 3 Interventional Results available

TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections

NCT01421511
View directory record Official record
Conditions
Skin and Subcutaneous Tissue Bacterial Infections
Interventions
TR-701 FA, Linezolid
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
666 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
35
States / cities
Dothan, Alabama • Chula Vista, California • Escondido, California + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Sep 3, 2026, 7:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare Oral Formulations of Tedizolid Phosphate in Healthy Adults (MK-1986-044)

NCT06609161
View directory record Official record
Conditions
Healthy
Interventions
Tedizolid Phosphate Oral Formulation 1 (Reference), Tedizolid Phosphate Oral Formulation 2 (Test)
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
19 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Sep 3, 2026, 7:27 AM EDT
Completed Phase 1 Interventional

A Pharmacokinetics and Safety Study in Subjects With Renal Impairment

NCT01452828
View directory record Official record
Conditions
Renal Impairment
Interventions
TR-701 FA single infusion, TR-701 FA
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Orlando, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 2, 2016 · Synced Sep 3, 2026, 7:27 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Safety and Exploratory Skin Lesion Measurement of TR-701 FA Study

NCT01519778
View directory record Official record
Conditions
Major Cutaneous Abscess, Cellulitis, Erysipelas
Interventions
TR701 FA
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
10
States / cities
Anaheim, California • Buena Park, California • Chula Vista, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Sep 3, 2026, 7:27 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure Infections

NCT00761215
View directory record Official record
Conditions
Skin Diseases, Infectious, Skin Diseases, Bacterial
Interventions
TR-701 200 mg, TR-701 300 mg, TR-701 400 mg
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 75 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
12
States / cities
Dothan, Alabama • Chula Vista, California • Long Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Sep 3, 2026, 7:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Open-Label, 10 Day Safety Study

NCT01623401
View directory record Official record
Conditions
Healthy Subjects
Interventions
TR-701 FA
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Sep 3, 2026, 7:27 AM EDT